| 7023-5 |
Kanamycin.high potency |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Kanamycin.high potency [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
7023-5 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Kanamycin High Pot Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Kanamycin High Pot; Kanamycin synergy; Kantrex; KB; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Synergistic |
2.19 |
1.0h(2) |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70230-8 |
Feeling distant or cut off from other people in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Feeling distant or cut off from other people in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70230-8 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
10 |
Feeling distant or cut off from other people? |
N |
|
1 month; 1 month (30 days); 30 days; Feeling cut off from other people; Finding; Findings; month; Ordinal; Othr; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70231-6 |
Feeling emotionally numb or being unable to have loving feelings for those close to you in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Feeling emotionally numb or being unable to have loving feelings for those close to you in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70231-6 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
11 |
Feeling emotionally numb or being unable to have loving feelings for thos close to you? |
N |
|
1 month; 1 month (30 days); 30 days; Feel emotionally numb in last Mo; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70232-4 |
Feeling as if your future will somehow be cut short in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Feeling as if your future will somehow be cut short in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70232-4 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
12 |
Feeling as if your future will somehow be cut short? |
N |
|
1 month; 1 month (30 days); 30 days; Arterial Stenosis; Feeling future will be cut short; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70233-2 |
Trouble falling or staying asleep in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Trouble falling or staying asleep in the last month [PCL-C] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70233-2 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
13 |
Trouble falling or staying asleep? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70234-0 |
Feeling irritable or having angry outbursts in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Feeling irritable or having angry outbursts in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70234-0 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
14 |
Feeling irritable or having angry outbursts? |
N |
|
1 month; 1 month (30 days); 30 days; Feeling irritable having angry outbursts; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70235-7 |
Having difficulty concentrating in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Having difficulty concentrating in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70235-7 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
15 |
Having difficulty concentrating? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70236-5 |
Being super alert or watchful on guard in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Being super alert or watchful on guard in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70236-5 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
16 |
Being super alert or watchful on guard? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70237-3 |
Feeling jumpy or easily startled in the last Mo |
Find |
^Patient |
1Mo |
Ord |
PCL-C |
|
ACTIVE |
Feeling jumpy or easily startled in the last month [PCL-C] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MTLHLTH |
|
70237-3 |
|
PCL-C |
|
|
|
|
|
|
0 |
|
|
17 |
Feeling jumpy or easily startled? |
N |
|
1 month; 1 month (30 days); 30 days; Finding; Findings; month; Ordinal; Past; Post traumatic stress disorder (PTSD) checklist - civilian version; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH |
2.54 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70238-1 |
Progress note |
Find |
Hospital |
Pt |
Doc |
Transplant surgery |
|
ACTIVE |
Transplant surgery Hospital Progress note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
70238-1 |
|
Transplant surgery |
|
|
Both |
|
|
|
0 |
Transpl surg Hosp Prog note |
|
|
|
N |
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; Hosp; Inpatient; notes; Point in time; Prog note; Random; subsequent evaluation; subsequent visit evaluation; Surg; Transpl surg; Visit note |
2.73 |
2.4 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70239-9 |
Testosterone |
SCnc |
Ser/Plas |
Pt |
Qn |
Detection limit <= 3.47 pmol/L |
|
ACTIVE |
Testosterone [Moles/volume] in Serum or Plasma by Detection limit <= 3.47 pmol/L |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
70239-9 |
|
Detection limit <= 3.47 pmol/L |
|
|
Both |
|
|
|
0 |
Testost SerPl DL<= 3.47 pmol/L-sCnc |
|
|
|
N |
|
Chemistry; DL<= 3.47 pmol/L; Left; Level; Levo; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Testo; Testos; Testost |
2.73 |
2.4 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 7024-3 |
Kanamycin.high potency |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Kanamycin.high potency [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
7024-3 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Kanamycin High Pot Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Kanamycin High Pot; Kanamycin synergy; Kantrex; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Synergistic |
2.19 |
1.0h(2) |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 70240-7 |
Testosterone.free |
SCnc |
Ser/Plas |
Pt |
Qn |
Detection limit <= 3.47 pmol/L |
|
ACTIVE |
Testosterone Free [Moles/volume] in Serum or Plasma by Detection limit <= 3.47 pmol/L |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
70240-7 |
|
Detection limit <= 3.47 pmol/L |
|
|
Both |
|
|
|
0 |
Testost Free SerPl DL<= 3.47 pmol/L-sCnc |
|
|
|
N |
|
Chemistry; DL<= 3.47 pmol/L; FR; Left; Level; Levo; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Testo; Testos; Testost; Testost Free; Testosterone.unconjugated |
2.73 |
2.4 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 70241-5 |
HIV 1 RNA |
NCnc |
Plas |
Pt |
Qn |
Probe.amp.tar detection limit = 20 copies/mL |
|
ACTIVE |
HIV 1 RNA [#/volume] (viral load) in Plasma by Probe and target amplification method detection limit = 20 copies/mL |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
70241-5 |
|
Probe.amp.tar detection limit = 20 copies/mL |
|
|
Both |
|
|
|
0 |
HIV1 RNA # Plas NAA DL=20 |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; AIDS; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; DNA NUCLEIC ACID PROBE; DNA probe; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA DL=20; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.4 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 70242-3 |
Shigella species+EIEC invasion plasmid antigen H (ipaH) gene |
PrThr |
Stool |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
positive negative |
|
|
|
|
|
MICRO |
|
70242-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Shigella sp+EIEC ipaH Stl Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Ag; Amplif; Amplification; Amplified; Bowel movement; DNA NUCLEIC ACID PROBE; DNA probe; EIEC; enteroinvasive E coli; enteroinvasive Escherichia coli; Faecal; Faeces; Fecal; Feces; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Shigella; Shigella sp+EIEC; Shigella sp+EIEC ipaH; Shigellosis; Stl; Stool = Fecal; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.73 |
2.4 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70243-1 |
CLN3 gene exon 7+8 deletion |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
CLN3 gene exon 7+8 deletion [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70243-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CLN3 exon 7+8 Del Bld/T Ql |
|
|
|
N |
|
1.02 kb deletion; 1.02-KB DEL; 1.02kB deletion; 1kb deletion; Batten disease; Blood; BTS; c.461-280_677+382del; CLN3 exon 7+8; CLN3, 1.02-KB DEL; Del; Deletions; Genetics; Heredity; Heritable; Inherited; JNCL; juvenile-onset neuronal ceroid lipo-fuscinosis; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70244-9 |
CFTR gene.c.394delTT |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
CFTR gene c.394delTT [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70244-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CFTR c.394delTT Bld/T Ql |
|
|
|
N |
|
2-BP DEL, 394TT; ABC35; ABCC7; Blood; CBAVD; CF; CFA; CFTR 2 base pair deletion; CFTR 2-BP DEL; CFTR c.394delTT; CFTR/MRP; Cystic fibrosis transmembrane conductance regulator; cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7); dJ760C5.1; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MRP7; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; TNR-CFTR; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70245-6 |
PAH gene.p.Arg408Trp |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
PAH gene.p.Arg408Trp [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70245-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PAH p.R408W Bld/T Ql |
|
|
|
N |
|
12q23.2; ARG408TRP; Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; P prime; PAH p.R408W; PAH, ARG408TRP; PCR; PH; phenylalanine hydroxylase; Phenylalanine hydroxylase gene; PHENYLKETONURIA; PKU; PKU1; Point in time; PR; QL; Qual; Qualitative; Random; rs5030858; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal. Changed Component name to align with the current HGVS recommendations to use the three letter codes for amnio acids. In the shortname, we kept the single letter codes.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70246-4 |
CCR2 gene.p.Val64Ile |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
CCR2 gene p.Val64Ile [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70246-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CCR2 p.V64I Bld/T Ql |
|
|
|
N |
|
Blood; CC-CKR-2; CCR-2; CCR2 p.V64I; CCR2A; CCR2B; CD192; CKR2; CKR2A; CKR2B; CMKBR2; Genetics; Heredity; Heritable; Inherited; MCP-1-R; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; P prime; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal. Changed Component name to align with the current HGVS recommendations to use the three letter codes for amnio acids. In the shortname, we kept the single letter codes.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70247-2 |
CCR5 gene.c.794_825del |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
CCR5 gene c.794_825del [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70247-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CCR5 c.794_825del Bld/T Ql |
|
|
|
N |
|
32 bp deletion; 32bp deletion; Blood; CCCKR5; CC-CKR-5; CCR-5; CCR5 c.794_825del; CD195; Chemokine (C-C motif) receptor 5; chemokine (C-C motif) receptor 5 (gene/pseudogene); CKR5; CKR-5; CMKBR5; Genetics; Heredity; Heritable; IDDM22; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70248-0 |
GALT gene.p.Gln188Arg |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
GALT gene p.Gln188Arg [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Wild type/Heterozygote/Homozygote |
|
|
|
|
|
MOLPATH.MUT |
|
70248-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
GALT p.Q188R Bld/T Ql |
|
|
|
N |
|
Blood; galactose-1-phosphate uridylyltransferase; Galactose-1-phosphate uridylyltransferase gene; GALT p.Q188R; Genetics; GLN188ARG; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; P prime; PCR; Point in time; PR; QL; Qual; Qualitative; Random; rs75391579; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.4 |
|
|
|
|
|
|
|
|
|
|
Property has been changed from Arb (arbitrary) to Pr (presence) to reflect our current model for Ordinal terms where the results are based on the presence or absence of a mutation or variant. Scale has been changed from Nom to Ord since results (e.g. present/absent or wildtype, heterozgous, homozygous) are ordinal. Changed Component name to align with the current HGVS recommendations to use the three letter codes for amnio acids. In the shortname, we kept the single letter codes.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 7025-0 |
Ketoconazole |
Susc |
Isolate |
Pt |
OrdQn |
Gradient strip |
|
ACTIVE |
Ketoconazole [Susceptibility] by Gradient strip |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
7025-0 |
|
Gradient strip |
|
|
Observation |
|
|
|
0 |
Ketoconazole Islt Grad strip |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Epsilometer; Estrip; E-strip; Grad strip; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MIC; Minimum inhibitory concentration; Nizoral; NZ; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.56 |
1.0h(2) |
|
|
|
|
|
|
|
|
|
|
Feb 2016-removed "E-test" from the short and long names because the "ETEST" name is trademarked |
0 |
| 70251-4 |
Pyruvate dehydrogenase Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Pyruvate dehydrogenase IgG Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
70251-4 |
|
IA |
|
|
Both |
|
|
|
0 |
PDH IgG Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Dehydrog; Dehyrdogenase; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; Immune globulin G; Immunoglobulin G; MEIA; PDH; Point in time; Pyruvic acid; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SUDS |
2.7 |
2.4 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70252-2 |
Islet cell 512 Ab.IgG |
PrThr |
Ser/Plas |
Pt |
Ord |
IA |
|
ACTIVE |
Islet cell 512 IgG Ab [Presence] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
SERO |
|
70252-2 |
|
IA |
|
|
Both |
|
|
|
0 |
Islet Cell512 IgG SerPl Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Endocrine; Endocrinology; Enzyme immunoassay; IA2; IA-2; IA2-ab; IAA; ICA; ICA512; ICA-512; Immune globulin G; Immunoglobulin G; Islet Cell512; MEIA; Ordinal; Pl; Plasma; Plsm; Point in time; PR; protein tyrosine phosphatase-like protein IA2; PtP-IA2; QL; Qual; Qualitative; Random; Screen; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; Tyrosine phosphatase |
2.56 |
2.4 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 70253-0 |
Islet cell 512 Ab.IgG |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Islet cell 512 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
SERO |
|
70253-0 |
|
IA |
|
|
Both |
|
|
|
0 |
Islet Cell512 IgG SerPl IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Endocrine; Endocrinology; Enzyme immunoassay; IA2; IA-2; IA2-ab; IAA; ICA; ICA512; ICA-512; Immune globulin G; Immunoglobulin G; Islet Cell512; MEIA; Pl; Plasma; Plsm; Point in time; protein tyrosine phosphatase-like protein IA2; PtP-IA2; QNT; Quan; Quant; Quantitative; Random; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; Tyrosine phosphatase |
2.7 |
2.4 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
